Senomyx Inc. (SNMX) Jumps 9.42% on December 23

Equities Staff |

Senomyx Inc. (SNMX) was among the biggest gainers on the Russell 2000 for Wednesday December 23 as the stock popped 9.42% to $4.18, representing a gain of $0.36 per share. Some 427,018 shares traded hands on 2,182 trades, compared with an average daily volume of 289,709 shares out of a total float of 44.45 million. The stock opened at $3.85 and traded with an intraday range of $4.25 to $3.82.

After today's gains, Senomyx Inc. reached a market cap of $185.78 million. Senomyx Inc. has had a trading range between $7.80 and $3.58 over the last year, and it had a 50-day SMA of $4.57 and a 200-day SMA of $5.27.

Senomyx Inc discovers, develops and commercializes flavor ingredients for the packaged food, beverage and ingredient supply industries by including savory and cooling flavors and flavor modulators, such as sweet and salt modifiers and bitter blockers.

Senomyx Inc. is based out of San Diego, CA and has some 110 employees. Its CEO is John Poyhonen.

For a complete fundamental analysis analysis of Senomyx Inc., check out Equities.com’s Stock Valuation Analysis report for SNMX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

D-Wave

D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…